These results are comparable with those reported earlier.17,20,21 The results of retrospective pooled analysis from randomized CRYSTAL and OPUS trials showed that cetuximab as the first-line chemotherapy based on irinotecan or oxaliplatin significantly improved OS, ORR and PFS the in patients with wt-KRAS tumours. This evidence concerns the gene KRAS and neoplasm.